CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

NCT05122546 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Advanced Clear Cell Renal Cell Carcinoma
Advanced Papillary Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Sarcomatoid Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Metastatic Papillary Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Metastatic Sarcomatoid Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Clear Cell Renal Cell Carcinoma
Unresectable Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib S-malate
DRUG: Clostridium butyricum CBM 588 Probiotic Strain
BIOLOGICAL: Nivolumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]